vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and Urban Edge Properties (UE). Click either name above to swap in a different company.

Urban Edge Properties is the larger business by last-quarter revenue ($132.6M vs $74.7M, roughly 1.8× Health Catalyst, Inc.). Urban Edge Properties runs the higher net margin — 17.1% vs -121.9%, a 139.0% gap on every dollar of revenue. On growth, Urban Edge Properties posted the faster year-over-year revenue change (12.2% vs -6.2%). Over the past eight quarters, Urban Edge Properties's revenue compounded faster (11.6% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.

HCAT vs UE — Head-to-Head

Bigger by revenue
UE
UE
1.8× larger
UE
$132.6M
$74.7M
HCAT
Growing faster (revenue YoY)
UE
UE
+18.4% gap
UE
12.2%
-6.2%
HCAT
Higher net margin
UE
UE
139.0% more per $
UE
17.1%
-121.9%
HCAT
Faster 2-yr revenue CAGR
UE
UE
Annualised
UE
11.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
HCAT
HCAT
UE
UE
Revenue
$74.7M
$132.6M
Net Profit
$-91.0M
$22.6M
Gross Margin
Operating Margin
-115.3%
Net Margin
-121.9%
17.1%
Revenue YoY
-6.2%
12.2%
Net Profit YoY
-340.3%
-6.7%
EPS (diluted)
$-1.29
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
UE
UE
Q1 26
$132.6M
Q4 25
$74.7M
$119.6M
Q3 25
$76.3M
$120.1M
Q2 25
$80.7M
$114.1M
Q1 25
$79.4M
$118.2M
Q4 24
$79.6M
$116.4M
Q3 24
$76.4M
$112.4M
Q2 24
$75.9M
$106.5M
Net Profit
HCAT
HCAT
UE
UE
Q1 26
$22.6M
Q4 25
$-91.0M
$12.4M
Q3 25
$-22.2M
$14.9M
Q2 25
$-41.0M
$58.0M
Q1 25
$-23.7M
$8.2M
Q4 24
$-20.7M
$30.1M
Q3 24
$-14.7M
$9.1M
Q2 24
$-13.5M
$30.8M
Gross Margin
HCAT
HCAT
UE
UE
Q1 26
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Operating Margin
HCAT
HCAT
UE
UE
Q1 26
Q4 25
-115.3%
11.3%
Q3 25
-22.9%
13.4%
Q2 25
-46.0%
53.9%
Q1 25
-25.4%
7.6%
Q4 24
-22.0%
27.6%
Q3 24
-17.9%
8.9%
Q2 24
-20.8%
30.6%
Net Margin
HCAT
HCAT
UE
UE
Q1 26
17.1%
Q4 25
-121.9%
10.4%
Q3 25
-29.1%
12.4%
Q2 25
-50.8%
50.8%
Q1 25
-29.9%
6.9%
Q4 24
-26.0%
25.9%
Q3 24
-19.3%
8.1%
Q2 24
-17.8%
28.9%
EPS (diluted)
HCAT
HCAT
UE
UE
Q1 26
$0.18
Q4 25
$-1.29
$0.09
Q3 25
$-0.32
$0.12
Q2 25
$-0.59
$0.46
Q1 25
$-0.35
$0.07
Q4 24
$-0.33
$0.25
Q3 24
$-0.24
$0.07
Q2 24
$-0.23
$0.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
UE
UE
Cash + ST InvestmentsLiquidity on hand
$95.7M
$50.0M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$1.4B
Total Assets
$502.6M
$3.4B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
UE
UE
Q1 26
$50.0M
Q4 25
$95.7M
$48.9M
Q3 25
$91.5M
$77.8M
Q2 25
$97.3M
$53.0M
Q1 25
$342.0M
$48.0M
Q4 24
$392.0M
$41.4M
Q3 24
$387.3M
$67.9M
Q2 24
$308.3M
$78.6M
Total Debt
HCAT
HCAT
UE
UE
Q1 26
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
HCAT
HCAT
UE
UE
Q1 26
$1.4B
Q4 25
$245.8M
$1.4B
Q3 25
$331.9M
$1.4B
Q2 25
$347.5M
$1.4B
Q1 25
$376.8M
$1.4B
Q4 24
$365.2M
$1.4B
Q3 24
$355.0M
$1.3B
Q2 24
$357.0M
$1.3B
Total Assets
HCAT
HCAT
UE
UE
Q1 26
$3.4B
Q4 25
$502.6M
$3.3B
Q3 25
$587.1M
$3.3B
Q2 25
$616.2M
$3.3B
Q1 25
$891.5M
$3.3B
Q4 24
$858.9M
$3.3B
Q3 24
$813.0M
$3.2B
Q2 24
$691.7M
$3.2B
Debt / Equity
HCAT
HCAT
UE
UE
Q1 26
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
UE
UE
Operating Cash FlowLast quarter
$9.9M
$39.1M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
1.5%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
UE
UE
Q1 26
$39.1M
Q4 25
$9.9M
$182.7M
Q3 25
$-464.0K
$55.7M
Q2 25
$-9.0M
$43.5M
Q1 25
$280.0K
$32.6M
Q4 24
$-3.5M
$153.2M
Q3 24
$6.2M
$36.6M
Q2 24
$1.6M
$41.2M
Free Cash Flow
HCAT
HCAT
UE
UE
Q1 26
Q4 25
$9.6M
$81.8M
Q3 25
$-719.0K
$26.1M
Q2 25
$-9.2M
$19.6M
Q1 25
$-390.0K
$11.9M
Q4 24
$-3.9M
$42.5M
Q3 24
$5.5M
$12.2M
Q2 24
$1.3M
$19.9M
FCF Margin
HCAT
HCAT
UE
UE
Q1 26
Q4 25
12.9%
68.4%
Q3 25
-0.9%
21.7%
Q2 25
-11.4%
17.2%
Q1 25
-0.5%
10.0%
Q4 24
-4.9%
36.6%
Q3 24
7.2%
10.8%
Q2 24
1.7%
18.6%
Capex Intensity
HCAT
HCAT
UE
UE
Q1 26
1.5%
Q4 25
0.4%
84.4%
Q3 25
0.3%
24.6%
Q2 25
0.3%
20.9%
Q1 25
0.8%
17.5%
Q4 24
0.5%
95.1%
Q3 24
0.9%
21.7%
Q2 24
0.4%
20.1%
Cash Conversion
HCAT
HCAT
UE
UE
Q1 26
1.73×
Q4 25
14.71×
Q3 25
3.73×
Q2 25
0.75×
Q1 25
3.97×
Q4 24
5.09×
Q3 24
4.03×
Q2 24
1.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

UE
UE

Rental revenue$124.2M94%
Other$8.4M6%

Related Comparisons